Noticias y eventos de Moderna Inc (MRNA)MRNAModerna Inc

Stocks Broadly Lower Following Fed Chair Speech

Stocks ended the day broadly lower following Federal Reserve Chair Kevin Warsh's speech at the Jackson Hole symposium. In his first major speech since taking the chair in May, Warsh warned that inflation has not meaningfully slowed, signaling that policymakers may have "work to do" to bring inflation back down to the Fed's 2% target.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Advent and Stripe are no longer pursuing a $50B deal for PayPal,Marvellreportedand provided guidance for Q3Gapprovided a "beat and raise" report for Q2Element Solutionsand Solstice Advanced Materialsmutually agreed toGE Vernovanamed Rivian's2. WALL STREET CALLS:Modernato Buy at Argus after FDA approval for updated Covid vaccinesWorkdayto Equalweight at Capital OneTeraWulfwith an Outperform at William BlairEvolution Petroleumto Outperform at NorthlandAllstateto Hold at Argus3. AROUND THE WEB:The U.S. appeals court sided with Nevada regulators, allowing the state to treat sports prediction markets like unlicensed sportsbooks, while sending Kalshi's election contracts back for further consideration, Bloomberg Law reportsChevronappears positioned to invest billions of dollars and expand its Venezuela footprint, while Halliburtoncould benefit from increased oilfield services activity, WSJ reportsAnthropic discussed buying AI chip startup MatX for about $7B, but talks are no longer active, Reuters saysKimberly-Clarkhas asked EU regulators permission for its proposed $40B takeover of Kenvue, Reuters reportsSoftBankis in talks to buy a majority stake in humanoid robot maker 1X at a $6B valuation, The Information says4. MOVERS:Elasticadvanced after, providing guidance for Q2, and raising its outlook for FY27PagerDutygained afterand raising its guidance for FY27N-ablewas higher after announcing a $50M increase to itsRubrikfell afterand raising its guidance for FY27BioNTechwas lower in New York after announcing it will terminate its5. EARNINGS/GUIDANCE:Chase, with EPS beating consensusFiscalNoteprovidedMiniso, with CEO Guofu Ye "pleased to see that MINISO Chinese mainland delivered a standout performance"Koss Corp., with EPS and revenue higher year-over-yearAffirmand provided guidance for Q1 and FY27INDEXES:The Dow fell 9.45, or 0.02%, to 53,559.99, the Nasdaq lost 138.93, or 0.52%, to 26,402.42, and the S&P 500 declined 19.23, or 0.25%, to 7,711.76.

Major Averages Rise After Fed Chair's Speech

The major averages were higher near noon after Federal Reserve Chair Kevin Warsh's speech at the Jackson Hole symposium. In his first major speech since taking the chair in May, Warsh warned that inflation has not meaningfully slowed, signaling that policymakers may have "work to do" to bring inflation back down to the Fed's 2% target.The Treasury market remains a risk as long-term yields have risen sharply in recent weeks, with the 30-year yield near levels last seen in 2007. Treasury Secretary Scott Bessent's expanded bond-buyback program has attempted to ease pressure at the long end of the curve, but investors remain concerned about inflation, government borrowing and the fiscal outlook.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Advent and Stripe are no longer pursuing a $50B deal for PayPal,Marvellreportedand provided guidance for Q3Gapprovided afor Q2Element Solutionsand Solstice Advanced Materialsmutually agreed toGE Vernovanamed Rivian's2. WALL STREET CALLS:Modernato Buy at Argus after FDA approval for updated Covid vaccinesWorkdayto Equalweight at Capital OneTeraWulfwith an Outperform at William BlairEvolution Petroleumto Outperform at NorthlandAllstateto Hold at Argus3. AROUND THE WEB:Chevronappears positioned to invest billions of dollars and expand its Venezuela footprint, with a potential addition of two heavy-oil fields, while Halliburtoncould benefit from increased oilfield services activity, WSJ reportsAnthropic discussed buying AI chip startup MatX for about $7B, but talks are no longer active, Reuters saysKimberly-Clarkhas asked EU regulators permission for its proposed $40B takeover of Kenvue, Reuters reportsSoftBankis in talks to buy a majority stake in humanoid robot maker 1X at a $6B valuation, The Information saysYouTubeand TikTok are yet to publicly acknowledge Meta'sproposed changes under its AG settlement, NY Times reports4. MOVERS:Elasticincreases after, providing guidance for Q2, and raising its outlook for FY27PagerDutygains afterand raising its guidance for FY27N-ablehigher after announcing a $50M increase to itsRubrikfalls afterand raising its guidance for FY27BioNTechlower in New York after announcing it will terminate itsof a cancer vaccine5. EARNINGS/GUIDANCE:Chasewith EPS beating consensusFiscalNoteMiniso, with CEO Guofu Ye "pleased to see that MINISO Chinese mainland delivered a standout performance"Koss Corp., with EPS and revenue higher year-over-yearAffirmand provided guidance for Q1 and FY27INDEXES:Near midday, the Dow was up 94.13, or 0.18%, to 53,663.57, the Nasdaq was up 51.28, or 0.19%, to 26,592.63, and the S&P 500 was up 16.06, or 0.21%, to 7,747.05.

Moderna Announces $2.6B Convertible Senior Notes Offering

Moderna announced the pricing of $2.6B aggregate principal amount of 0.00% Convertible Senior Notes due 2032 in a private placement only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended. The offering was upsized from the previously announced offering size of $2.0B aggregate principal amount of the notes. Moderna has also granted the initial purchasers of the notes an option to purchase, for settlement during a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $400.0 million aggregate principal amount of the notes. The sale of the notes to the initial purchasers is expected to close on September 1, 2026. The conversion rate will initially be 4.7487 shares of Moderna's common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $210.58 per share of Moderna's common stock). The initial conversion price represents a premium of approximately 47.5% over the last reported sale price of $142.77 per share of Moderna's common stock on the Nasdaq Global Select Market on August 27, 2026.